Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In a report released yesterday, Lili (Aurélie) Nsongo from Leerink Partners maintained a Hold rating on Arcturus Therapeutics ( ARCT – Research Report ), with a price target of $63.00. Discover ...

View Our Latest Stock Analysis on ARCT Arcturus Therapeutics Stock Performance ARCT stock opened at $10.53 on Friday. The business has a 50-day simple moving average of $13.26 and a two-hundred ...

SAN DIEGO - Arcturus Therapeutics Holdings Inc. (NASDAQ ... While the company's stock has faced challenges, declining over 69% in the past year, InvestingPro analysis suggests the stock may ...

Shares of Vertex Pharmaceuticals Inc. plunged 10.03% to $450.03 Tuesday, on what proved to be an all-around grim trading ...

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting ...

Arcturus Therapeutics Holdings Inc. ARCT announced ... NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base ...